The company turning magic mushrooms into actual medicine.

A laboratory in a Seattle suburb, quietly cataloguing the chemistry of the mind

In a low building on East Sunset Way in Issaquah, Washington - the kind of street that has a coffee shop and very little else - a small team is solving crystal structures of molecules most people have only encountered as folklore. This is CaaMTech. There is no neon, no influencer, no microdosing app. There is a compound library, a stack of more than 100 patent filings, and a founder who treats psilocybin the way a metallurgist treats an alloy.

The psychedelics industry spent the last decade selling the experience - the trip, the breakthrough, the testimonial. CaaMTech sells something less photogenic and far more durable: knowledge of what the molecules actually are. It is a drug discovery company, not a clinic and not a retreat. Its product is characterization, optimization, and the intellectual property that comes from doing the homework first.

You cannot patent a mushroom, and you cannot fund what you cannot patent

Here is the inconvenient truth at the center of psychedelic medicine. The famous compounds - psilocybin, DMT, mescaline - have been known for generations. They are, in patent terms, prior art. Nature published first. And modern drug development costs hundreds of millions of dollars, money that no rational investor commits to a molecule anyone can copy.

So the field had a paradox: enormous therapeutic promise, almost nothing patentable to build a company around. Most founders responded by reformulating the same handful of known molecules and hoping the delivery method was novel enough to defend. CaaMTech looked at the same wall and decided to walk around it - by making new molecules entirely.

It sounds simple. It is not. To make a new psychedelic compound that a regulator and a clinician will trust, you have to know its structure precisely - down to how the atoms are arranged in a crystal. Skip that step and you have a curiosity, not a candidate. CaaMTech decided the unglamorous step was the whole game.

A chemist who also happened to be a patent attorney

Andrew Chadeayne is an unusual combination: trained as a chemist, credentialed as a patent attorney. After what he has described as a nice exit from an earlier venture, he asked himself the question most people only daydream about - what would you do if you never had to work again? His answer was to go back into the lab. He founded CaaMTech in 2016, when the psychedelic market was barely a market at all.

The bet was that science and intellectual property were not separate departments but the same activity. Every new compound CaaMTech synthesized and characterized was simultaneously a research result and a defensible asset. Where others saw a regulatory minefield, Chadeayne saw open chemical territory that nobody had bothered to map - and mapping it carefully would produce both the medicine and the patent.

Note the modesty of the ambition. Not one miracle drug - more tools. CaaMTech is built around the idea that mental health is too varied for a single molecule, and that the right answer is a diverse library from which clinicians can choose. Personalized medicine, assembled one tryptamine at a time.

The entourage effect, borrowed from cannabis and applied to mushrooms

Magic mushrooms are not a single drug. They are a cocktail - psilocybin alongside lesser-known molecules like baeocystin, norbaeocystin, and the rare aeruginascin. CaaMTech's central insight is that these companions are not noise. They may be the difference between a useful experience and a frightening one. Borrowing a term usually reserved for cannabis, the company calls this the entourage effect.

Chase that idea and you arrive at a tantalizing prospect: a mushroom redesigned to keep the therapeutic benefit while dialing down the bad trip. CaaMTech is especially interested in aeruginascin, which some researchers believe may blunt the potential for a negative experience. The trouble is that aeruginascin is rare and expensive to produce. So the company did what chemists do - it engineered around the cost.

More tools, not one miracle

Depression is not one disease, and PTSD is not one wound. CaaMTech's mission follows from that fact. Rather than betting everything on a single molecule and a single trial, the company is trying to expand the toolbox - to give clinicians a range of well-characterized, patentable options and let the treatment fit the patient instead of the other way around.

There is also a quieter principle here: collaborative science over commercial gatekeeping. CaaMTech publishes structures, partners with universities, and treats open chemistry as an accelerant rather than a leak. For a company whose moat is intellectual property, that is a deliberate and slightly contrarian choice - the sort of contradiction that tends to mark people who actually enjoy the work.

Back to the building on East Sunset Way

Return to that quiet street in Issaquah. The coffee shop is still there. The lab is still small. But the work happening inside has changed what the rest of the field can do. The molecules CaaMTech mapped, the structures it solved, the patents it filed - these are now the scaffolding other companies build on, whether they cite it or not.

The next decade of mental-health medicine will not be won by whoever throws the best retreat. It will be won by whoever did the chemistry. CaaMTech made that bet in 2016, before it was fashionable, and has spent ten years quietly proving it. The trip was never the product. The understanding was.

A small team in a Seattle suburb decided to learn exactly what these molecules are. Everything else - the medicine, the patents, the patients - depends on that.